MA42519A - Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique - Google Patents

Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique

Info

Publication number
MA42519A
MA42519A MA042519A MA42519A MA42519A MA 42519 A MA42519 A MA 42519A MA 042519 A MA042519 A MA 042519A MA 42519 A MA42519 A MA 42519A MA 42519 A MA42519 A MA 42519A
Authority
MA
Morocco
Prior art keywords
treatment
diabetic nephropathy
pde4 inhibitor
pde4
inhibitor
Prior art date
Application number
MA042519A
Other languages
English (en)
Inventor
Guido Hanauer
Masatoshi Hazama
Takanori Matsuo
Stephanie Vollert
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of MA42519A publication Critical patent/MA42519A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA042519A 2015-07-29 2016-07-28 Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique MA42519A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562198213P 2015-07-29 2015-07-29

Publications (1)

Publication Number Publication Date
MA42519A true MA42519A (fr) 2018-06-06

Family

ID=56551407

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042519A MA42519A (fr) 2015-07-29 2016-07-28 Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique

Country Status (9)

Country Link
US (1) US20200179369A1 (fr)
EP (1) EP3328381A1 (fr)
JP (1) JP2018521077A (fr)
CN (1) CN108135886A (fr)
BR (1) BR112018001116A2 (fr)
CA (1) CA2992796A1 (fr)
EA (1) EA201890346A1 (fr)
MA (1) MA42519A (fr)
WO (1) WO2017017165A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3503892A1 (fr) * 2016-08-26 2019-07-03 Takeda GmbH Traitement de la stéatose hépatique non alcoolique
CN119523985A (zh) * 2017-05-27 2025-02-28 青岛海蓝医药有限公司 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
CN114053281B (zh) * 2020-08-10 2025-05-27 成都文鼎科技发展有限公司 治疗慢性肾病的方法和药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508358A (ja) * 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
PL2589599T4 (pl) * 2004-03-03 2015-06-30 Takeda Gmbh Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method

Also Published As

Publication number Publication date
WO2017017165A1 (fr) 2017-02-02
CA2992796A1 (fr) 2017-02-02
EA201890346A1 (ru) 2018-08-31
JP2018521077A (ja) 2018-08-02
BR112018001116A2 (pt) 2018-09-11
US20200179369A1 (en) 2020-06-11
EP3328381A1 (fr) 2018-06-06
CN108135886A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3288592A4 (fr) Utilisation de cannabidiol pour le traitement de spasmes infantiles
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
EP3313325A4 (fr) Échafaudages implantables pour le traitement de la sinusite
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
IL256209A (en) Novel cannabinoid combination therapies for multiple myeloma (mm)
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
EP3383547A4 (fr) Ensembles électromagnétiques pour le traitement de fluides
EP3503890A4 (fr) Utilisation de la pridopidine pour le traitement des dystonies
EP3351189A4 (fr) Instrument de traitement pour endoscope
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3328374A4 (fr) Antagonistes de la glutamine pour le traitement de déficits cognitifs
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
EP3375108A4 (fr) Traitement dewlan
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3386967A4 (fr) Combinaisons pour le traitement de calculs rénaux
EP3349793A4 (fr) Anti-s100a8 pour le traitement de la leucémie